Drug Information

Drug General Information
Drug ID
D05INV
Former ID
DNCL002557
Drug Name
PEGPH20
Indication Pancreatic cancer [ICD9: 140-199, 140-229, 157, 210-229; ICD10:C25] Phase 2 [524270]
Company
Halozyme Therapeutics San Diego, CA
Target and Pathway
Target(s) Hyaluronidase Target Info Modulator [1572591]
References
Ref 524270ClinicalTrials.gov (NCT01839487) PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. U.S. National Institutes of Health.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.